PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 16962127-1 2006 Epinephrine QT stress testing is an effective diagnostic tool to unmask concealed Long QT Syndrome (LQTS), particularly type 1 LQTS (LQT1). Epinephrine 0-11 potassium voltage-gated channel subfamily Q member 1 Homo sapiens 133-137 19964641-3 2009 LQT1 patients show increased variability of repolarization with epinephrine infusion, as measured from the 12-lead ECG. Epinephrine 64-75 potassium voltage-gated channel subfamily Q member 1 Homo sapiens 0-4 16275192-5 2005 In contrast, QTc was significantly and consistently longer in subjects with LQT1 compared with controls during and after exercise (492 +/- 40 vs 407 +/- 14 ms, p <0.0001, at peak exercise; 498 +/- 30 vs 399 +/- 20 ms, p <0.0001, at 1 minute into recovery) or epinephrine (623 +/- 51 vs 499 +/- 51 ms, p <0.001, at peak epinephrine; 604 +/- 36 vs 507 +/- 54 ms, p <0.01, at 1 minute into recovery) but not in subjects with LQT2. Epinephrine 265-276 potassium voltage-gated channel subfamily Q member 1 Homo sapiens 76-80 16534005-1 2006 BACKGROUND: A paradoxical increase in the uncorrected QT interval during infusion of low-dose epinephrine appears pathognomonic for type 1 long-QT syndrome (LQT1). Epinephrine 94-105 potassium voltage-gated channel subfamily Q member 1 Homo sapiens 157-161 16275192-5 2005 In contrast, QTc was significantly and consistently longer in subjects with LQT1 compared with controls during and after exercise (492 +/- 40 vs 407 +/- 14 ms, p <0.0001, at peak exercise; 498 +/- 30 vs 399 +/- 20 ms, p <0.0001, at 1 minute into recovery) or epinephrine (623 +/- 51 vs 499 +/- 51 ms, p <0.001, at peak epinephrine; 604 +/- 36 vs 507 +/- 54 ms, p <0.01, at 1 minute into recovery) but not in subjects with LQT2. Epinephrine 328-339 potassium voltage-gated channel subfamily Q member 1 Homo sapiens 76-80 15851169-2 2004 BACKGROUND: A differential response of dynamic QT interval to epinephrine infusion between LQT1, LQT2, and LQT3 syndromes has been reported, indicating the potential diagnostic value of the epinephrine test for genotyping the three forms. Epinephrine 62-73 potassium voltage-gated channel subfamily Q member 1 Homo sapiens 91-95 15851286-2 2005 BACKGROUND: QT prolongation is a paradoxical, LQT1-specific response to low-dose epinephrine infusion. Epinephrine 81-92 potassium voltage-gated channel subfamily Q member 1 Homo sapiens 46-50 15851286-8 2005 During epinephrine infusion, G1- and G2-T waves were more common in LQT2 than in LQT1 (75% vs 26%, P = .009). Epinephrine 7-18 potassium voltage-gated channel subfamily Q member 1 Homo sapiens 81-85 15851286-10 2005 Epinephrine-precipitated biphasic T waves were observed similarly in all groups: LQT1 (6/30), LQT2 (3/28), and control (4/32). Epinephrine 0-11 potassium voltage-gated channel subfamily Q member 1 Homo sapiens 81-85 15851286-11 2005 During low-dose epinephrine infusion (< or =0.05 microg/kg/min), G1-T waves occurred more frequently in LQT2 (LQT1: 25% vs 3%; control 9%, P = .02). Epinephrine 16-27 potassium voltage-gated channel subfamily Q member 1 Homo sapiens 113-117 15851288-9 2005 DeltaQT, SD-DeltaQT, and QTI were increased in LQT1 but not in control patients during epinephrine (LQT1: DeltaQT 2.3-4.2 ms, SD-DeltaQT 2.2-4.1, QTI 0.10-0.22, P < .005 vs baseline; CONTROL: DeltaQT 2.5-2.4 ms, SD-DeltaQT 1.9-2.1, QTI 0.08-0.09: P = NS vs baseline). Epinephrine 87-98 potassium voltage-gated channel subfamily Q member 1 Homo sapiens 47-51 15851288-10 2005 CONCLUSIONS: Beat-by-beat QT variability analyzed by the cross-correlation method was greater in LQT1 patients during epinephrine infusion, suggesting sympathetic stimulation accentuates beat-by-beat alternation of repolarization in LQT1 patients. Epinephrine 118-129 potassium voltage-gated channel subfamily Q member 1 Homo sapiens 97-101 15851288-10 2005 CONCLUSIONS: Beat-by-beat QT variability analyzed by the cross-correlation method was greater in LQT1 patients during epinephrine infusion, suggesting sympathetic stimulation accentuates beat-by-beat alternation of repolarization in LQT1 patients. Epinephrine 118-129 potassium voltage-gated channel subfamily Q member 1 Homo sapiens 233-237 15733182-1 2005 AIMS: To explore effects of epinephrine and phenylephrine on the behavior of right ventricular monophasic action potentials (MAPs) in symptomatic LQT1 and LQT2 patients. Epinephrine 28-39 potassium voltage-gated channel subfamily Q member 1 Homo sapiens 146-150 15733182-5 2005 Epinephrine prolonged MAP50-to-MAP90 duration and increased the rate dependence of MAP90 duration and increased restitution rate in type LQT1, but not in LQT2 patients nor in control subjects. Epinephrine 0-11 potassium voltage-gated channel subfamily Q member 1 Homo sapiens 137-141 15851169-2 2004 BACKGROUND: A differential response of dynamic QT interval to epinephrine infusion between LQT1, LQT2, and LQT3 syndromes has been reported, indicating the potential diagnostic value of the epinephrine test for genotyping the three forms. Epinephrine 190-201 potassium voltage-gated channel subfamily Q member 1 Homo sapiens 91-95 15851169-6 2004 RESULTS: The sensitivity (penetrance) by ECG diagnostic criteria was lower in LQT1 (68%) than in LQT2 (83%) or LQT3 (83%) before epinephrine and was improved with steady-state epinephrine in LQT1 (87%) and LQT2 (91%) but not in LQT3 (83%), without the expense of specificity (100%). Epinephrine 176-187 potassium voltage-gated channel subfamily Q member 1 Homo sapiens 78-82 15851169-6 2004 RESULTS: The sensitivity (penetrance) by ECG diagnostic criteria was lower in LQT1 (68%) than in LQT2 (83%) or LQT3 (83%) before epinephrine and was improved with steady-state epinephrine in LQT1 (87%) and LQT2 (91%) but not in LQT3 (83%), without the expense of specificity (100%). Epinephrine 176-187 potassium voltage-gated channel subfamily Q member 1 Homo sapiens 191-195 15851169-9 2004 CONCLUSIONS: Epinephrine infusion is a powerful test to predict the genotype of LQT1, LQT2, and LQT3 syndromes as well as to improve the clinical diagnosis of genotype-positive patients, especially those with LQT1 syndrome. Epinephrine 13-24 potassium voltage-gated channel subfamily Q member 1 Homo sapiens 80-84 12598076-1 2003 OBJECTIVES: This study was designed to test the hypothesis that epinephrine infusion may be a provocative test able to unmask nonpenetrant KCNQ1 mutation carriers. Epinephrine 64-75 potassium voltage-gated channel subfamily Q member 1 Homo sapiens 139-144 12598076-8 2003 CONCLUSIONS: Epinephrine challenge is a powerful test to establish electrocardiographic diagnosis in silent LQT1 mutation carriers, thus allowing implementation of prophylactic measures aimed at reducing sudden cardiac death. Epinephrine 13-24 potassium voltage-gated channel subfamily Q member 1 Homo sapiens 108-112 12431311-7 2002 In this review article, sympathetic stimulation with isoproterenol or epinephrine infusion is demonstrated to modulate differentially these repolarization indices in the ECG as well as the action potentials of the three cells between the LQT1, LQT2, and LQT3 syndromes both experimentally and clinically, explaining the differences in the sensitivity of genotypes of congenital LQTS to sympathetic stimulation. Epinephrine 70-81 potassium voltage-gated channel subfamily Q member 1 Homo sapiens 238-242 12004990-7 2002 During epinephrine infusion, every LQT1 patient manifested prolongation of the QT interval (paradoxical response), whereas healthy controls and patients with either LQT2 or LQT3 tended to have shortened QT intervals (P<.001). Epinephrine 7-18 potassium voltage-gated channel subfamily Q member 1 Homo sapiens 35-39 12004990-10 2002 Low-dose epinephrine (0.05 microg x kg(-1) x min(-1)) completely discriminated LQT1 patients (AQT, +82+/-34 ms) from controls (AQT, -7+/-13 ms; P<.001). Epinephrine 9-20 potassium voltage-gated channel subfamily Q member 1 Homo sapiens 79-83 12004990-12 2002 CONCLUSIONS: Epinephrine-induced prolongation of the QT interval appears pathognomonic for LQT1. Epinephrine 13-24 potassium voltage-gated channel subfamily Q member 1 Homo sapiens 91-95 12004990-13 2002 Low-dose epinephrine infusion distinguishes controls from patients with concealed LQT1 manifesting an equivocal QTc at rest. Epinephrine 9-20 potassium voltage-gated channel subfamily Q member 1 Homo sapiens 82-86 11394742-5 2001 A novel clinical test involving an epinephrine challenge in the decedent"s mother implicated a potential defect in the phase 3 potassium current encoded by the gene KVLQT1. Epinephrine 35-46 potassium voltage-gated channel subfamily Q member 1 Homo sapiens 165-171 11693770-8 2001 The epinephrine-induced increases in the mean QTc-e and Tcp-e were larger in LQT1 than in LQT2, and were more pronounced when the averaged data were obtained from 24-leads than from 87-leads. Epinephrine 4-15 potassium voltage-gated channel subfamily Q member 1 Homo sapiens 77-81 9593563-1 1998 BACKGROUND: This study used monophasic action potential (MAP) to examine the effect of nicorandil, a K+ channel opener, on repolarization abnormalities induced by epinephrine in the LQT1 form of congenital long-QT syndrome in which the KvLQT1 mutation underlies the defect in the channel responsible for the slowly activating component of the delayed rectifier potassium current. Epinephrine 163-174 potassium voltage-gated channel subfamily Q member 1 Homo sapiens 182-186 9593563-3 1998 In LQT1 patients, epinephrine infusion prolonged the QT interval and 90% MAP duration (MAPD90) and increased the dispersion of MAPD90. Epinephrine 18-29 potassium voltage-gated channel subfamily Q member 1 Homo sapiens 3-7 32437023-1 2020 BACKGROUND: The epinephrine infusion test (EIT) typically induces marked QT prolongation in LQT1, but not LQT3, while the efficacy of beta-blocker therapy is established in LQT1, but not LQT3. Epinephrine 16-27 potassium voltage-gated channel subfamily Q member 1 Homo sapiens 92-96